Heart Failure in Acute Pulmonary Hypertension

  • R. M. Prewitt
  • J. Ducas
Part of the Update in Intensive Care and Emergency Medicine book series (UICM, volume 6)


Pulmonary hypertension may be present in a variety of clinical conditions. For example, certain patients with the Adult Respiratory Distress Syndrome (ARDS) may develop severe pulmonary hypertension as a consequence of the underlying lung disease [1]. The increase in right ventricular (RV) afterload may decrease cardiac output (CO) and tissue O2 delivery and may impair survival [1, 2,]. In another example, short-term mortality is reported to increase when hypotension complicates pulmonary emboli. For example, mortality in patients, where the diagnosis has been confirmed angiographically is reported to be 6%, increasing to greater than 30% if hypotension develops [3, 4].


Pulmonary Hypertension Right Ventricular Pulmonary Vascular Resistance Adult Respiratory Distress Syndrome Right Ventricular Function 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Zapol WM, Snider MT (1977) Pulmonary hypertension in severe acute respiratory failure. N Engl J Med 296: 476–480PubMedCrossRefGoogle Scholar
  2. 2.
    Laver MB, Strauss WH, Pojost GM (1979) Herbert Shubin Memorial Lecture - Right and left ventricular geometry: Adjustments during acute respiratory failure. Crit Care Med 7: 509–519PubMedCrossRefGoogle Scholar
  3. 3.
    Alpert JS, Smith R, Carlson J, Ockene IS, Dexter L, Dalen JE (1976) Mortality in patients treated for pulmonary embolism. JAMA 236: 1477–1480PubMedCrossRefGoogle Scholar
  4. 4.
    Urokinase Pulmonary Embolism Study Group: Urokinase pulmonary embolism trial (1973) Circulation 47:66–73Google Scholar
  5. 5.
    Stein PD, Sabbah HN, Anbe DT, Marzilli M (1979) Performance of the failing and nonfailing right ventricle of patients with pulmonary hypertension. Am J Cardiol 44: 1050–1055PubMedCrossRefGoogle Scholar
  6. 6.
    Ghignone M, Girling L, Prewitt RM (1984) Effect of increased pulmonary vascular resistance on right ventricular systolic performance in dogs. Am J Physiol 246 (Heart Circ Physiol 15): H339 - H343PubMedGoogle Scholar
  7. 7.
    Vlahakes GJ, Turley K, Hoffman JIE (1981) The pathophysiology of failure in acute right ventricular hypertension: Hemodynamic and biochemical correlations. Circulation 63: 87–95PubMedCrossRefGoogle Scholar
  8. 8.
    Scharf SM, Warner KG, Josa M, Brown R, Khursi SF (1986) Load tolerance of the right ventricle: Effect of increased aortic pressure. J Crit Care 1: 163–173CrossRefGoogle Scholar
  9. 9.
    Molloy WD, Lee KY, Girling L, Schick U, Prewitt RM (1984) Treatment of shock in a canine model of pulmonary embolism. Am Rev Respir Dis 130: 870–874PubMedGoogle Scholar
  10. 10.
    Prewitt RM, Matthay MA, Ghignone M (1984) Hemodynamic management in the adult respiratory distress syndrome. Cardio Clin 2: 287–304Google Scholar
  11. 11.
    Wolff FW (1981) Shock due to pulmonary embolism: treatment with 1-noradrenaline. Lancet 2: 72–73Google Scholar
  12. 12.
    Ghignone M, Girling L, Prewitt RM (1984) Volume expansion vs noradrenaline in treatment of a low cardiac output complicating an acute increase in right ventricular afterload in dogs. Anesthesiology 60: 48–51CrossRefGoogle Scholar
  13. 13.
    Mathru M, Venus B, Smith RA, Shirakawa Y, Sugiura A (1986) Treatment of low cardiac output complicating acute pulmonary hypertension in normovolemic goats. Crit Care Med 14: 120–124PubMedCrossRefGoogle Scholar
  14. 14.
    State D, Salisbury PF (1956) The experimental production of the pulmonary embolism syndrome and the effects of variations of systemic arterial pressure on its course. Cedars of Lebanon Hospital, Los Angeles, pp 202–208Google Scholar
  15. 15.
    Paetkau D, Kettner J, Girling L, Slykerman L, Prewitt R (1982) What is the appropriate therapy to maintain cardiac output as pulmonary vascular resistance increases? Anesthesiology 57 (3): A56CrossRefGoogle Scholar
  16. 16.
    Prewitt RM, Ducas J (1986) Pathophysiology and therapy of right ventricular dysfunction due to pulmonary embolism. In: Brest AN (ed) The right heart, Cardiovasc Clin 17: Chapter 14, F. A. Davis Company, Philadelphia, pp 191–202Google Scholar
  17. 17.
    Molloy WD, Lee KY, Jones D, Penner B, Prewitt RM (1985) Effects of noradrenaline and isoproterenol on cardiopulmonary function in a canine model of acute pulmonary hypertension. Chest 88: 432–435PubMedCrossRefGoogle Scholar
  18. 18.
    Dantzker DR, Bower JS (1981) Partial reversibility of chronic pulmonary hypertension caused by pulmonary thromboembolic disease. Am Rev Respir Dis 124: 129–131PubMedGoogle Scholar
  19. 19.
    Jardin F, Genevray B, Brunney JD, Margairaz A (1985) Dobutamine: A hemodynamic evaluation in pulmonary embolism shock. Crit Care Med 13: 1009–1012PubMedCrossRefGoogle Scholar
  20. 20.
    Snider MT, Rie MA, Lauer J, Zappol WM (1980) Normoxic pulmonary vasoconstriction in ARDS: Detection by sodium nitroprusside (N) and isoproterenol ( I) infusions. Am Rev Respir Dis (Suppl) 121: 191Google Scholar
  21. 21.
    Rubin LJ, Handel F, Peter RH (1982) The effects of oral hydralazine on right ventricular end diastolic pressure in patients with right ventricular failure. Circulation 65: 1369–1373PubMedCrossRefGoogle Scholar
  22. 22.
    Rubin LJ, Peter RH (1980) Oral hydralazine therapy for primary pulmonary hypertension. N Engl J Med 320: 69–73CrossRefGoogle Scholar
  23. 23.
    Rounds S, Kellet M, Jacobs A, Ryan T (1983) Failure of vasodilator responses in primary pulmonary hypertension. Am Rev Respir Dis (suppl) 127: 82AGoogle Scholar
  24. 24.
    Lee KY, Molloy DW, Slykerman L, Prewitt RM (1982) Effects of hydralazine and nitroprusside on cardiopulmonary function when a decrease in calic pressure in patients with right ventricular failure. Circulation 65: 1369–1373CrossRefGoogle Scholar
  25. 25.
    Sibbald WJ, Driedger AA, McCallum D, Cunningham DG, Cheung H (1986) Nitroprusside infusion does not improve biventricular performance in patients with acute hypoxemic respiratory failure. J Crit Care 1 (4): 197–203CrossRefGoogle Scholar
  26. 26.
    Packer MB, Greenberg B, Massie B, Dash H (1982) Deleterious effects of hydralazine in patients with pulmonary hypertension. N Engl J Med 306: 1326–1331PubMedCrossRefGoogle Scholar
  27. 27.
    D’Ambra MN, LaRaia PJ, Philbin DM, Watkins WD, Hilgenberg AD, Buckley MJ (1985) Prostaglandin E. A new therapy for refractory right heart failure and pulmonary hypertension after mitral valve replacement. J Thorac Cardiovasc Surg 89: 567–572PubMedGoogle Scholar
  28. 28.
    Urokinase-Streptokinase Embolism Trial Phase 2 Results: A Cooperative Study (1974) JAMA 229:1606–1613Google Scholar
  29. 29.
    Urokinase Pulmonary Embolism Trial (UPET) (1973) Circulation 47 (suppl II): 1–108Google Scholar
  30. 30.
    Petitpretz P, Simmoneau G, Cerrina J, et al (1984) Effects of a single bolus of urokinase in patients with life-threatening pulmonary emboli: A descriptive trial. Circulation 70: 861–866PubMedCrossRefGoogle Scholar
  31. 31.
    Chesebro JH, Knatterud G, Roberts R, et al (1987) Thrombolysis in myocardial infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase* Clinical findings through hospital discharge. Circulation 76: 142–154PubMedCrossRefGoogle Scholar
  32. 32.
    Verstraete M, Brower RW, Collen D, et al (1985) Double-blind randomized trial of intravenous tissue-type plasminogen activator versus placebo in acute myocardial infarction. Lancet 2: 965–969PubMedCrossRefGoogle Scholar
  33. 33.
    Williams DO, Borer J, Braunwald E, et al (1986) Intravenous recombinant tissue-type plasminogen activator in patients with acute myocardial infarction: a report from the NHLBI thrombolysis in myocardial infarction trial. Circulation 73 (2): 338–346PubMedCrossRefGoogle Scholar
  34. 34.
    Van, de Werf F, Bergmann SR, Fox KAA et al (1984) Coronary thrombolysis with intravenously administered human tissue-type plassminogen activator produced by recombinant DNA technology. Circulation 69: 605–610PubMedCrossRefGoogle Scholar
  35. 35.
    Agnelli G, Buchanan MR, Fernandez F, Van Ryn J, Hirch J (1985) Sustained thrombolysis with DNA-recombinant tissue-type plasminogen activator in rabbits. Blood 66: 399–401PubMedGoogle Scholar
  36. 36.
    Bounameaux H, Vermylen J, Collen D (1985) Thrombolytic treatment with recombinant tissue-type plasminogen activator in a patient with massive pulmonary embolism. Ann Intern Med 103: 64–66PubMedGoogle Scholar
  37. 37.
    Goldhaber SZ, Meyerovitz MF, Markis JE, et al (1987) Thrombolytic therapy of acute pulmonary embolism: current status and future potential. J Am Coll Cardiol 10: 96B - 104BPubMedCrossRefGoogle Scholar
  38. 38.
    Prewitt RM, Papadimitropoulos R, Hasinoff I, et al (1987) Treatment of embolic pulmonary hypertension: tissue plasminogen activator vs. streptokinase (STK) vs. heparin. Clin Invest Med 5 (suppl C) 14: C32Google Scholar
  39. 39.
    Milnor WR (1982) Hemodynamics. Baltimore, Williams and Wilkins, pp 17–19Google Scholar
  40. 40.
    Chien S, Usami S, Skalak R (1984) Blood flow in small tubes. In: Handbook of physiology. Section 2: Cardiovascular system, vol. 4. Bethesda, MD Am Physiol Society, pp 217–219Google Scholar
  41. 41.
    Graham R, Skoog C, Macedo W, et al (1983) Dopamine, dobutamine, and phentolamine effects of pulmonary vascular mechanics. J Appl Physiol 54: 1277–1283PubMedGoogle Scholar
  42. 42.
    Mitzner W (1983) Resistance of the pulmonary circulation. Clin Chest Med 4 (2): 127–137PubMedGoogle Scholar
  43. 43.
    Shoukas AA, Brunner MJ, Frankle AE, Greene AS, Kailman CH (1984) Carotid sinus baroreceptor reflex control and the role of autoregulation in the system and pulmonary arterial pressure-flow relationships in a dog. Circ Res 54: 674–682PubMedGoogle Scholar
  44. 44.
    Mink SN, Unruh HW, Oppenheimer L (1985) Vascular and interstitial mechanics in canine pulmonary emphysema. J Appl Physiol 59 (6): 1704–1715PubMedGoogle Scholar
  45. 45.
    Ducas J, Girling L, Schick U, Prewitt RM (1986) Pulmonary vascular effects of hydralazine in a canine preparation of pulmonary thromboembolism. Circulation 73: 1050–1057PubMedCrossRefGoogle Scholar
  46. 46.
    Mitzner W, Sylvester JT (1981) Hypoxic vasoconstriction and fluid filtration in pig lungs. J Appl Physiol 51: 1065–1071PubMedGoogle Scholar
  47. 47.
    Mitzner W (1974) Hepatic outflow resistance, sinusoid pressure, and the vascular waterfall. Am J Physiol 227: 513–519PubMedGoogle Scholar
  48. 48.
    Graham R, Skoog C, Oppenheimer L, Rabson J, Goldberg HS (1982) Critical closure in the canine pulmonary vasculature. Circ Res 50: 566–572PubMedGoogle Scholar
  49. 49.
    Ducas J, Schick U, Girling L, Prewitt RM (1988) Effects of altered left atrial pressure on the pulmonary vascular pressure-flow relationship. Am J Physiol (Heart Circ Physiol) (in press)Google Scholar
  50. 50.
    Permutt S, Riley RL (1963) Hemodynamic of collapsible vessels with tone: The vascular waterfall. J Appl Physiol 18: 924–932PubMedGoogle Scholar
  51. 51.
    Hasinoff I, Ducas J, Papadimitropoulos R, Prewitt RM (1987) Characterization of the effective vascular waterfall (VM) produced by pulmonary emboli (PE). Clin Invest Med 10 (suppl): C480Google Scholar
  52. 52.
    Ducas J, Duval D, Dasilva H, Boiteau P, Prewitt RM (1987) Treatment of canine pulmonary hypertension: Effects of norepinephrine and isoproterenol on pulmonary vascular pressure-flow characteristics. Circulation 75: 235–242PubMedCrossRefGoogle Scholar
  53. 53.
    Boiteau P, Ducas J, Schick U, Girling L, Prewitt RM (1986) Pulmonary vascular pressure-flow relationship in canine oleic acid pulmonary edema. Am J Physiol 251 (Heart Circ Physiol 20): H1163 - H1170PubMedGoogle Scholar
  54. 54.
    Wang CG, Hakim TS, Michel RP, Chang HK (1985) Segmental pulmonary vascular resistance in progressive hydrostatic and permeability edema. J Appl Physiol 59: 242–247PubMedGoogle Scholar
  55. 55.
    DaSilva H, Boiteau P, Girling L, Schick U, Ducas J, Prewitt RM (1986) The effects of isoproterenol on canine pulmonary vascular pressure-flow relationship after autologous blood clot emboli. Am Rev Resp Dis 133 (suppl): 400AGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1988

Authors and Affiliations

  • R. M. Prewitt
  • J. Ducas

There are no affiliations available

Personalised recommendations